EVFM Stock Overview
A biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Evofem Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0094 |
| 52 Week High | US$0.075 |
| 52 Week Low | US$0.006 |
| Beta | -0.88 |
| 1 Month Change | -4.08% |
| 3 Month Change | -5.05% |
| 1 Year Change | -85.56% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Evofem partners with a360 Media to support Phexxi prescription growth
Jul 21Evofem announces peer-reviewed publication on birth control method
Jul 12Female Contraception Post Roe V. Wade - Evofem CEO Saundra Pelletier
Jul 06Evofem announces U.S. patent win for birth control method
Jun 30Evofem: ACA Coverage Of Phexxi Is A Game Changer
Jan 18Shareholder Returns
| EVFM | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -3.1% | -1.5% | -2.4% |
| 1Y | -85.6% | 7.9% | 23.4% |
Return vs Industry: EVFM underperformed the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: EVFM underperformed the US Market which returned 23.4% over the past year.
Price Volatility
| EVFM volatility | |
|---|---|
| EVFM Average Weekly Movement | 15.7% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: EVFM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: EVFM's weekly volatility has decreased from 23% to 16% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 38 | Saundra Pelletier | www.evofem.com |
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis.
Evofem Biosciences, Inc. Fundamentals Summary
| EVFM fundamental statistics | |
|---|---|
| Market cap | US$1.07m |
| Earnings (TTM) | -US$11.02m |
| Revenue (TTM) | US$17.10m |
0.1x
P/S Ratio-0.1x
P/E RatioIs EVFM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EVFM income statement (TTM) | |
|---|---|
| Revenue | US$17.10m |
| Cost of Revenue | US$3.28m |
| Gross Profit | US$13.82m |
| Other Expenses | US$24.84m |
| Earnings | -US$11.02m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.097 |
| Gross Margin | 80.84% |
| Net Profit Margin | -64.45% |
| Debt/Equity Ratio | -67.5% |
How did EVFM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 11:01 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Evofem Biosciences, Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Tanner | Cantor Fitzgerald & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| I-Eh Jen | Laidlaw & Company (UK) Ltd |